Reply to Antonio Cigliola, Andrea Necchi, and Umberto Capitanio’s Letter to the Editor Re: Metastasis-directed Therapy with or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol 2026;90:13–18
Reply to Antonio Cigliola, Andrea Necchi, and Umberto Capitanio’s Letter to the Editor Re: Metastasis-directed Therapy with or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol 2026;90:13–18. // European Urology. – URL: https://www.sciencedirect.com/science/article/pii/S0302283826022566?dgcid=rss_sd_all
Reply to Antonio Cigliola, Andrea Necchi, and Umberto Capitanio’s Letter to the Editor Re: Metastasis-directed Therapy with or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol 2026;90:13–18. European Urology. https://www.sciencedirect.com/science/article/pii/S0302283826022566?dgcid=rss_sd_all
“Reply to Antonio Cigliola, Andrea Necchi, and Umberto Capitanio’s Letter to the Editor Re: Metastasis-directed Therapy with or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol 2026;90:13–18.” European Urology.
@article{article118623,
title = {Reply to Antonio Cigliola, Andrea Necchi, and Umberto Capitanio’s Letter to the Editor Re: Metastasis-directed Therapy with or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol 2026;90:13–18},
journal = {European Urology},
url = {https://www.sciencedirect.com/science/article/pii/S0302283826022566?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...